Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Blood Adv · 2022 · PMC9631625 · PMID 35728048

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the rate was higher with eprenetapopt+azacitidine at 33% vs 22% with azacitidine alone, this did not reach statistical significance. 37 Encouraging early-phase results have been reported with venetoclax+azacitidine in patients with higher-risk MDS, 35 but the data from the randomized VERONA trial are awaited (trial currently ongoing, # NCT04401748 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.